Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.

doi:10.1016/j.immuni.2021.03.023

Article

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.

Immunity - 8 Jun 2021

Graham Carl, Seow Jeffrey, Huettner Isabella, Khan Hataf, Kouphou Neophytos, Acors Sam, Winstone Helena, Pickering Suzanne, Galao Rui Pedro, Dupont Liane, Lista Maria Jose, Jimenez-Guardeño Jose M, Laing Adam G, Wu Yin, Joseph Magdalene, Muir Luke, van Gils Marit J, Ng Weng M, Duyvesteyn Helen M E, Zhao Yuguang, Bowden Thomas A, Shankar-Hari Manu, Rosa Annachiara, Cherepanov Peter, McCoy Laura E, Hayday Adrian C, Neil Stuart J D, Malim Michael H, Doores Katie J

Abstract excerpt

Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To...

Topics

Join the communities discussing this publication.

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.

Abstract excerpt

Topics

Discuss the evidence

Related research